A few days ago, I listened to an interview with Econtalk with Eric Topol, a cardiologist at Las Roberts, about health issues associated with health issues. In total, I am more and more interested in the issue.
An interesting problem arises at about 36:00 points. Topol States:
We need to use better nanoparticles and ensure that their mRNA does not fall into unpleasant side effects. But we don’t have it. The companies that create these are packed with the original version. But we got about a billion people exposed to them.
Lass follows up on this later:
When you say that companies are sticking to the original version of Theur, do the intellectual property protection baker it relies on saying it’s expensive?
The Lath is on subthing: cost starting from scratch.
Topol Responts:
No, I think part of that is intellectual property. Part of that is going to mass-produce hundreds of millions of vaccines and go to a new process – the points are: It has been found that penetration is improved because nanoparticles can be optimized. We have street self-amplifying vaccines in town where you give many small mRNAs. And it is approved in Japan. But there’s not even a little effort to make it happen in the US. It helps reduce the side effects of mRNA.
So these companies worked well during the pandemic and moved things straight away. That’s great; however, they haven’t caught up to the field. And we see the innovations we need in other parts of the world.
The lack of topol is the reason why there is progress in Japan, which has not been reproduced in the United States.
The answer is the Food and Drug Administration. Since the change in law in 1962, pharmaceutical companies wanting to introduce drugs into the favorable US market have shown not only safety but effectiveness. Requirements for effectiveness have been added to the drug development process in almost ten years.
Therefore, the problem is not the intellectual property itself. It means that the process of obtaining approval runs through.
As Dan Klein argues, it makes sense that the FDA automatically approves drugs approved by FDA counterparts.
You might argue that it is too dangerous. However, if you don’t like the risk, wait for FDA Apppoves to unlock. Others can take the opportunity. That’s the wonderful thing about freedom. I need more.
